TOP STORIES
respiratory
ILD

Antifibrotic agent slows progression of RA-ILD


Nintedanib slows the rate of decline in forced vital capacity (FVC) in patients with progressive fibrosing RA associated interstitial lung disease (RA-ILD), according to a UK study. A subanalysis of the INBUILD trial comprised 89 patients with RA-ILD of which 42...

Nintedanib slows the rate of decline in forced vital capacity (FVC) in patients with progressive fibrosing RA associated interstitial lung...

Read more